<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037450</url>
  </required_header>
  <id_info>
    <org_study_id>6528</org_study_id>
    <nct_id>NCT03037450</nct_id>
  </id_info>
  <brief_title>Miniinvasive Corneal Neurotization. A Pilot Study.</brief_title>
  <acronym>MICORNE</acronym>
  <official_title>Miniinvasive Corneal Neurotization. A Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurotrophic keratitis (NK) is a degenerative disease of the cornea due to the impairment of&#xD;
      the nasociliary branch of the ophthalmic nerve. Reduced corneal sensation lead to several&#xD;
      corneal lesions including spontaneous ulcerations, delayed wound healing, corneal scarring,&#xD;
      neovascularization, thinning, perforation or infection. An important and permanent visual&#xD;
      loss of is frequently associated with the condition. NK can be congenital or acquired. Its&#xD;
      acquired forms can be due to traumatic, infectious (herpes, zoster), neoplastic or iatrogenic&#xD;
      causes. There is currently no specific medical treatment. Surgical reconstruction techniques&#xD;
      of sensory neurotizations have recently been described in young patients suffering traumatic,&#xD;
      congenital or neoplastic NK using supratrochlear nerves as the sensory donor nerves and sural&#xD;
      nerve as healthy graft. A neurotization involves the transfer of a healthy donor nerve&#xD;
      segment into a tissue to reestablish either motor or sensory innervation. The aim of the&#xD;
      present study is to assess the outcomes of a novel sensory neurotization technique for the&#xD;
      treatment of severe NK in adult patients (Stages 2 and 3 of Mackie classification). Corneal&#xD;
      neurotizations will be performed using either ipsilateral supraorbital nerve as donor nerve&#xD;
      (direct neurotization) or contralateral supraorbital nerve as donor nerve and a segment of&#xD;
      the lateral antebrachial cutaneous nerve as graft. Small-size skin incisions (less than 3&#xD;
      centimeters) will be made in one or both eyebrow and an endoscopic device will help the&#xD;
      surgeons to localize and dissect the supraorbital nerve. Donor nerves or graft will be&#xD;
      sutured to the neurotrophic corneas. Adult patients with unilateral NK due to infectious,&#xD;
      traumatic or iatrogenic causes will be included.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The reasons for stopping the research are :&#xD;
&#xD;
      -  Inclusion difficulties (demanding inclusion and exclusion criteria),&#xD;
&#xD;
      -  The Covid-19 pandemic&#xD;
  </why_stopped>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">January 22, 2019</completion_date>
  <primary_completion_date type="Actual">January 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal sensation scores.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Neurotrophic Keratitis</condition>
  <arm_group>
    <arm_group_label>Miniinvasive corneal neurotization</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Miniinvasive corneal neurotization</intervention_name>
    <description>Neurotization of a neurotrophic cornea</description>
    <arm_group_label>Miniinvasive corneal neurotization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient older than 18.&#xD;
&#xD;
          -  NK stages 2 and 3 (Mackie's classification).&#xD;
&#xD;
          -  Non-response to maximal medical treatment (lachrymal substitution, autologous serum).&#xD;
&#xD;
          -  Postherpetic or post-zoster NK (Group 1).&#xD;
&#xD;
          -  Postoperative NK (neurosurgery and trigeminal thermocoagulation) (Group 2).&#xD;
&#xD;
          -  Posttraumatic NK (orbital trauma, ocular burn) (Group 3).&#xD;
&#xD;
          -  No ocular hypertony in both eyes.&#xD;
&#xD;
          -  Visual acuity &gt; 20/40 on the contralateral eye.&#xD;
&#xD;
          -  Written consent of the patient.&#xD;
&#xD;
          -  Patient benefiting from national health coverage (either as a direct user or&#xD;
             beneficiary).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossibility of general anesthesia.&#xD;
&#xD;
          -  Herpetic or zoster recurrence in the 6 months prior surgery.&#xD;
&#xD;
          -  Length of NK evolution &gt; 5 years.&#xD;
&#xD;
          -  Congenital NK.&#xD;
&#xD;
          -  Bilateral NK.&#xD;
&#xD;
          -  Other causes of NK: diabeta mellitus, amylosis, sarcoidosis, multiple sclerosis,&#xD;
             vitamin A or B12 deficiency, Sjögren syndrome, GVH disease, topical NSAID, topical&#xD;
             beta-blockers, history of refractive surgery.&#xD;
&#xD;
          -  Mental illness.&#xD;
&#xD;
          -  Adult with legal guardian or guardianship.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Breast-feeding.&#xD;
&#xD;
          -  Patient's unable to understand informations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

